SSelectStock
Sign in

LUPINLupin Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

2,478.70
1.45%
80Strong

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,12,900.40
P/E21.21
P/B5.03
PEG0.24
ROE %26.91
ROCE %50.50
Debt / Equity0.29
EPS116.40
Revenue Growth %31.90
Profit Growth %89.00
Dividend Yield %0.48
Promoter Holding %47.02
FII Holding %34.73
DII Holding %
Beta0.18

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG75%2,478.702,424.002,581.601.88
BUYConviction 87%

Why buy

  • Revenue growth: 31.9% YoY
  • Profit growth: 89.0% YoY
  • ROE: 26.9%
  • RSI: 60
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 75%)

Bull case

  • Revenue growth: 31.9% YoY
  • Profit growth: 89.0% YoY
  • ROE: 26.9%
  • RSI: 60

Bear case

  • Dividend yield: 0.48%
  • MACD: bearish
  • Volume: 0.7x 20-day average
  • Volume trend: 0.7x baseline

Key risks

  • Dividend yield: 0.48%
  • MACD: bearish

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹2,478.70
Stop Loss
₹2,357.42
risk 4.9%
Target 1 (1.5R)
₹2,660.62
+7.3%
Target 2 (3R)
₹2,842.53
+14.7%
Support (20d)
₹2,336.90
Resistance (52w)
₹2,526.90
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹121.28/share
ATR (volatility)
₹48.51
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹48.51). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
93
Technical
70
Momentum
72
Risk (safety)
86

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.39%
82
HESTERBIO 4.01%
81
SUNPHARMA 1.14%
79
GRANULES 0.65%
79
CORONA 0.76%
79

About

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.